The CEO's unplanned open-market sale immediately after a clinical failure and restructuring signals insider belief that the strategic alternatives process may not yield a favorable outcome for equity holders. Monitor for any definitive agreement or dissolution filing; the $319M cash cushion may attract acquirers but the clinical setback severely limits valuation.
Drugs in focus
ARTV drug pipeline →AB-101
● Neutral Named in this insider cluster- Impact
- Phase
- Phase 1a/1b
- Time to market
- AB-101 is in Phase 1a/1b trials; even if development proceeds smoothly, a potential approval is likely several years away given the early stage and the need for larger Phase 2 and Phase 3 trials.
- Next catalyst
- None dated
What to watchThe next catalyst for ABUS is Q3 2026 earnings on November 11, 2026 (tomorrow), which may include updates on AB-101's clinical development plans now that the FDA hold is lifted. For AB-101 specifically, watch for the company to announce the next phase of clinical trials in chronic hepatitis B patients. The clinical hold lift removes a key overhang, but the drug remains early-stage with no pivotal readout or PDUFA date on the horizon.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 4 $4.22entry
- T+1 · 12d ago −2.13%α +2.28% · $4.13
- T+5 · 6d ago −3.55%α −2.64% · $4.07
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
CEO and CMO sold shares days after the company discontinued its sole pipeline candidate, announced a 94% workforce reduction, and began evaluating strategic alternatives including a possible sale or dissolution. The CEO's $260K open-market sale is material relative to the $207M market cap (0.13%), signaling insider pessimism following the clinical failure.
Key Financial Metrics
Key Facts
- CEO Fred Aslan sold 62,178 shares at $4.18 for $260K on 2026-11-02, no 10b5-1 plan
- CMO Subhashis Banerjee sold 1,110 shares at $4.18 for $5K on 2026-11-02, no 10b5-1 plan
- On 2026-10-27, Artiva discontinued AlloNK (AB-101) after insufficient durability and two Grade 5 safety events
- Company reducing workforce by ~94% and exploring strategic alternatives including merger, sale, or dissolution
- Preliminary cash and investments were ~$319.1M as of Sep 30, 2026
- Total insider sales in the cluster: $265K, representing 0.13% of market cap
- Market cap: $207M; normal daily move: 3.8%
Financial Impact
CEO open-market sale of $260K (0.13% of market cap) days after clinical failure and restructuring announcement
Risk Factors
- Potential dissolution or fire-sale merger with limited equity value recovery
- Further insider selling as remaining executives exit
- No pipeline assets remaining after AlloNK discontinuation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ARTV-1793739928357 |
Track record
33 reports on ARTV
11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 16 of 18 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Viewing Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers